Tert-butyl 2,2-dimethylheptanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Tert-butyl 2,2-dimethylheptanoate
• 英文别名: tert-butyl 2,2-dimethylheptanoate
• 化学式: C₁₃H₂₆O₂
• 分子量: 214.34
• InChiKey: GKWZVNRAPOVRIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
  申请人：Gemphire Therapeutics Inc.

  公开号：US20160137584A1

  公开（公告）日：2016-05-19

  The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

  本公开提供了一种制备式（III）化合物、式（V）化合物和相应的式（IV）盐的过程。本发明的方法和过程制备的化合物特别适用于在人类和动物中使用。
• PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
  申请人：Gemphire Therapeutics Inc.

  公开号：EP3653598A1

  公开（公告）日：2020-05-20

  The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

  本发明提供了一种制备式（III）化合物、式（V）化合物和相应的式（IV）盐的工艺。通过本发明的方法和工艺制作的化合物特别适用于人类和动物的用药。
• Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers
  申请人：Gemphire Therapeutics Inc.

  公开号：US10227285B2

  公开（公告）日：2019-03-12

  The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

  本公开提供了一种制备式 (III) 化合物的工艺、 式（V）化合物、 和相应的式 (IV) 盐。 通过本发明的方法和工艺制作的化合物尤其适用于人类和动物的用药。
• Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
  申请人：LIXTE BIOTECHNOLOGY, INC.

  公开号：US10399993B2

  公开（公告）日：2019-09-03

  This invention provides compounds having the structure which may be used for the treatment of tumors.

  本发明提供了具有以下结构的化合物 可用于治疗肿瘤。
• Beta lactams as modulators of glutamate uptake and methods for use thereof
  申请人：Temple University—Of The Commonwealth System of Higher Education

  公开号：US10759750B2

  公开（公告）日：2020-09-01

  Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.

  本发明的药物组合物包括用于治疗药物成瘾、药物戒断以及病因中涉及谷氨酸平衡失调的疾病或病症的化合物、组合物和方法。